HRT Financial’s Biolase, Inc. BIOL Stock Holding History

HRT Financial’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-101,143	Closed	-$19K	–	3341
2024 Q1	$19K	Buy	+101,143	New	+$49.3K	﹤0.01%	2015
2023 Q3	–	Sell	-518	Closed	-$3K	–	3300
2023 Q2	$3K	Buy	+518	New	+$8.67K	﹤0.01%	2271
2023 Q1	–	Sell	-303	Closed	-$19K	–	3373
2022 Q4	$19K	Buy	+303	New	+$43.6K	﹤0.01%	2185
2022 Q2	–	Sell	-5	Closed	-$4K	–	3931
2022 Q1	$4K	Sell	5 -16	-76%	-$14.8K	﹤0.01%	2970
2021 Q4	$20K	Buy	+21	New	+$26.5K	﹤0.01%	2956

Other funds holding BIOL

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

HRT Financial's BIOL Position: Q2 2024 in Review

HRT Financial sold out of Biolase, Inc. (BIOL) in Q2 2024, closing a stake of 101,143 shares — an estimated $19K sold.

HRT Financial first reported a position in BIOL in Q4 2021 and held it in 5 quarters. The position peaked at $20K in Q4 2021. 2 funds tracked by Wall St. Rank hold BIOL as of Q2 2024.

HRT Financial reported no remaining Biolase, Inc. position as of Q2 2024 after selling out during the quarter.
HRT Financial sold 101,143 Biolase, Inc. shares in Q2 2024, an estimated $19K.
HRT Financial first reported a position in Biolase, Inc. in Q4 2021 and held it in 5 quarters.
HRT Financial's Biolase, Inc. position peaked at $20K in Q4 2021.
2 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2024.

Based on HRT Financial's 13F filing for Q2 2024, filed 12 Aug 2024.